

## 2015 Abstracts of SAKK and Collaborating Groups

### Gastrointestinal Cancers Symposium, San Francisco

#### Poster

**Helbling D. et al.** Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras unmutated, locally advanced rectal cancer (LARC): Final results of a randomized multicenter phase II trial (SAKK 41/07).

### 13th International Conference on Malignant Lymphoma in Lugano

#### Oral presentations

**Zucca E. et al.** Independent review of CT responses in the trial SAKK 35/10 comparing rituximab with or without lenalidomide in untreated follicular lymphoma patients in need of therapy.

**Hitz F. et al.** Rituximab, bendamustine and lenalidomide in patients with relapsed/refractory aggressive B-cell lymphoma not eligible for salvage chemotherapy. Phase II trial - SAKK 38/08

### 102. Jahreskongress der Schweizerischen Gesellschaft für Chirurgie in Bern

#### Oral presentations

**Hamel C. et al.** Factors influencing the surgeon`s decision to comply or not to comply with the assigned randomization for rectal replacement in a prospective randomized trial SAKK 40/04 comparing side-to-end anastomosis, colon-J-pouch, and straight coloanal anastomosis in patients with rectal cancer.

**Käser S. et al.** Does the radicality and quality of colorectal cancer surgery depend on the patient`s age?

**Käser S. et al.** Do cancers located at the hepatic or splenic flexure have a worse outcome compared to other colon cancers?

### Joint meeting of the International Biometric Society (IBS) Austro-Swiss and Italian Regions in Milano

#### Posters

**Bigler M. et al.** Comparison of design options for phase IB clinical trials in oncology: simulation results.

**Hayoz S. et al.** Effect of one-patient clusters on power in cluster-randomized trials.

## **2015 ASCO Annual Meeting in Chicago**

### **Poster**

**Ghadjar P. et al.** Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy. First results of the randomized trial SAKK 09/10.

**Kristeleit R. et al.** A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.

## **19th Annual SASRO Meeting in Basel**

### **Oral presentations**

**Herrmann E. et al.** External Beam Radiotherapy For Unresectable Hepatocellular Carcinoma. An International Multicenter Phase I Trial, SAKK 77/07

## **AACR Annual Meeting 2015 in Philadelphia**

### **Poster**

**Wicki A. et al.** First-in-man (FIM) pharmacodynamic (PD) and pharmacokinetic (PK) phase I trial of PQR309 in advanced solid tumours

## **World Congress of Surgery WCS 2015 in Bangkok**

### **Oral presentation**

**Curti G. et al.** Complication pattern according to hospital size in a prospective randomized trial SAKK 40/04 comparing colon-J-pouch, side-to-end anastomosis, and straight coloanal anastomosis after TME.

## **European Cancer Congress 2015 in Vienna**

### **Oral presentation**

**Cathomas R. et al.** Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11)

### **Poster discussion**

**Fischer S. et al.** Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma.

### **Poster**

**Jaggi R. et al.** A correlative study of Ki67 and two multigene RNA expression signatures in operable ER-positive postmenopausal breast cancer (SAKK 26/10).

**Pestalozzi B. et al.** Adjuvant treatment recommendations for ER+ early breast cancer patients by Swiss tumor boards (SAKK 26/10).

**Kienle D. et al.** Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10.

**Stathis A. et al.** A phase I study of the smoothed (SMO) antagonist LDE225 in combination with paclitaxel in patients with advanced solid tumors.

## 2015 ASTRO's Annual Meeting

### Poster

**Herrmann E. et al.** External Beam Radiotherapy For Unresectable Hepatocellular Carcinoma. An International Multicenter Phase I Trial, SAKK 77/07.

## 2015 San Antonio Breast Cancer Symposium

### Poster discussion

**Borgquist S. et al.** Cholesterol, cholesterol lowering medication use, and breast cancer outcomes in the BIG 1-98 study

### Posters

**Zweifel M. et al.** Phase 1 evaluation of the androgen receptor modulator CR1447 in patients with advanced breast cancer (SAKK 21/12).

**Pruneri G. et al.** Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple negative breast cancer treated by induction chemotherapy with or without oral low dose cyclophosphamide-methotrexate maintenance chemotherapy (CMM) (IBCSG 22-00)

**Pagani O. et al.** POSITIVE: A study evaluating pregnancy and disease outcome and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (IBCSG 48-14/BIG 8-13)

**Denkert C. et al.** Systematic analysis and modulation of Ki67 interobserver variance in 9069 patients from three clinical trials – How much pathologist concordance is needed for meaningful biomarker results?

**Willis S. et al.** Immune related gene expression signatures predict benefit of letrozole over tamoxifen in BIG 1-98

## 2015 ASH Annual Meeting

### Oral presentation

**Davies A. et al.** A prospective randomised trial of targeted therapy for diffuse large B-cell lymphoma (DLBCL) based upon real-time gene expression profiling: The REMoDL-B study of the UK NCRI and SAKK lymphoma groups, ISRCTN51837425